AWAK baggage $20M in Sequence B funding
Regardless of a difficult market situation, Singapore-based medtech AWAK Applied sciences has raised greater than $20 million in a Sequence B funding spherical – one of many greatest funding raises in Southeast Asia this 12 months. The spherical was co-led by Lion X Ventures and Vickers Enterprise Companions.
AWAK is creating a transportable peritoneal dialysis machine that permits customers to bear dialysis wherever, foregoing lengthy hours of stationary remedy and being linked to large-sized machines in hospitals and clinics.
Primarily based on a press launch, the proceeds from the funding spherical will go to finishing AWAK’s ongoing human scientific trial with Singapore Normal Hospital, which is being carried out forward of its closing pivotal trial in the USA in 2025.
The fund may even be used for creating complementary merchandise that promote house dialysis and combine digital options for enhancing home-based care of persistent kidney illness sufferers.
On-line pharmacy MedEasy nets $750k seed funding
MedEasy, a web based pharmacy in Bangladesh, has scored $750,000 in a seed funding spherical participated by Seedstars Worldwide Ventures, Doha Tech Angels, Startup Bangladesh Restricted, Accelerating Asia, and nVentures, amongst different buyers.
The funds might be used to refine its operation, improve its platform options, attain extra customers, and advance R&D, a press assertion stated.
Because it launched two years in the past, the startup has now over 150,000 customers. Apart from rising its buyer base, MedEasy additionally plans to launch a subscription-based function, a digital well being monitoring system, and an appointment-booking market.
Switzerland OKs DeepBio’s AI prostate most cancers analysis help software program
Medical AI startup DeepBio from South Korea has obtained regulatory approval from Switzerland for its AI-powered diagnostic help software program for prostate most cancers.
The Swiss Company for Therapeutic Merchandise has cleared DeepDx Prostate for commercialisation in Switzerland, in keeping with a press launch.
The AI product, which has additionally been permitted in Europe, analyses complete slide photographs of prostate needle biopsy tissues utilizing AI to detect and localise areas of curiosity and classify them by severity.
Samsung SDS-spinoff Wellysis’s ECG patch will get US FDA approval
Wellysis, a Samsung SDS spinoff firm based mostly in Seoul, has acquired the approval of the USA Meals and Drug Administration for its wearable ECG patch.
The S-Patch Ex includes a bio-processor for capturing correct ECG waveforms. The light-weight machine may be built-in with cellphones, tablets, and watches, and can also be appropriate with any commercially accessible electrodes and batteries.
The US FDA approval comes two years after the machine has been granted a CE mark in Europe. S-Patch Ex is presently being offered in 14 international locations worldwide, together with the UK, Australia, Thailand and India.